BRCA1 and breast cancer: A phase II clinical RCT by Tomasz Byrski et al. conducted a phase II study and showed that the clinical response rate is as high as 80% in those patients with metastatic BC with BRCA-1 gene mutation who received cisplatin monotherapy, and the clinicopathological remission rate is 45% [50].